Ono Pharma and Boehringer Ingelheim both added to their cancer pipelines, licensing drugs from LigaChem Bio and Circle Pharma ...

Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment ...

Boehringer Ingelheim is one of the world’s leading research-oriented pharmaceutical companies. The clinical pipeline is constantly being further developed, and Boehringer Ingelheim expects new ...

The rise in research and development activities in schizophrenia treatment is driving market growth by fostering the development of innovative therapies, including novel antipsychotics and ...

German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

AllianceQUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery 24.10.2024 / 09:30 CET/CESTThe issuer is solely responsible for the content of this ...

Our partner, Boehringer Ingelheim, is combining multiple Dark Antigens to create ... medicines and technologies that have the potential to enhance Pfizer's pipeline and shape the future of our ...

Boehringer Ingelheim and Circle Pharma have entered ... The latest deal will strengthen the oncology pipeline of Boehringer, which includes a range of cancer cell-directed and immuno-oncology ...

Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce ...